

Response to Office Action  
Serial No. 09/978,454  
Page 2 of 6

030727.0027.CON1

to charge trust account No. 50-1273 for the two -month extension fee due herein, and any other fees that may become due or credit become payable during the pendency of this application.

### AMENDMENTS

Please amend the claims to read as follows:

- E 2* 169. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA) or analogues thereof.
170. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA).
171. (Twice Amended) The pharmaceutical composition of claim 168, wherein MH is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, fludarabine, and 5-fluoro-2'-deoxyuridine.
172. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is radiolabelled 2'-deoxy-5-iodouridine.
173. (Once Amended) The pharmaceutical composition of claim 172 wherein MH is 2'-deoxy-5-<sup>131</sup>I-iodouridine.
174. (Once Amended) The pharmaceutical composition of claim 168, wherein V is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
175. (Once Amended) The pharmaceutical composition of claim 168, wherein the prodrug is in the *cis* configuration.
176. (Once Amended) The pharmaceutical composition of claim 174, wherein the prodrug is in the *cis* configuration.